Patrick R Lawler1,2,3,4, Akintunde O Akinkuolie1,3, Paul M Ridker2,3, Allan D Sniderman5, Julie E Buring3,4, Robert J Glynn3,4, Daniel I Chasman3, Samia Mora6,2,3. 1. Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 3. Preventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Harvard T.H. Chan School of Public Health, Boston, MA. 5. Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, QC, Canada. 6. Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; smora@partners.org.
Abstract
BACKGROUND: It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non-HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant. METHODS: Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models. RESULTS: Although all 3 biomarkers were correlated (r ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both P < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56-2.00) for apo B and 1.70 (1.50-1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07-1.39) for apo B and 1.13 (0.99-1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk. CONCLUSIONS: Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.
BACKGROUND: It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non-HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant. METHODS: Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models. RESULTS: Although all 3 biomarkers were correlated (r ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both P < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56-2.00) for apo B and 1.70 (1.50-1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07-1.39) for apo B and 1.13 (0.99-1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk. CONCLUSIONS: Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.
Authors: Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood Journal: Eur Heart J Date: 2011-06-28 Impact factor: 29.983
Authors: S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein Journal: JAMA Date: 2012-03-28 Impact factor: 56.272
Authors: Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur Journal: Can J Cardiol Date: 2013-02 Impact factor: 5.223
Authors: George Thanassoulis; Ken Williams; Keying Ye; Robert Brook; Patrick Couture; Patrick R Lawler; Jacqueline de Graaf; Curt D Furberg; Allan Sniderman Journal: J Am Heart Assoc Date: 2014-04-14 Impact factor: 5.501
Authors: Shafqat Ahmad; Samia Mora; Paul M Ridker; Frank B Hu; Daniel I Chasman Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai Journal: J Clin Lipidol Date: 2017-07-12 Impact factor: 4.766
Authors: Deirdre K Tobias; Patrick R Lawler; Paulo H Harada; Olga V Demler; Paul M Ridker; JoAnn E Manson; Susan Cheng; Samia Mora Journal: Circ Genom Precis Med Date: 2018-04
Authors: Shafqat Ahmad; Samia Mora; Paul W Franks; Marju Orho-Melander; Paul M Ridker; Frank B Hu; Daniel I Chasman Journal: Clin Chem Date: 2017-11-02 Impact factor: 8.327
Authors: Nicholas A Marston; Robert P Giugliano; Giorgio E M Melloni; Jeong-Gun Park; Valerie Morrill; Michael A Blazing; Brian Ference; Evan Stein; Erik S Stroes; Eugene Braunwald; Patrick T Ellinor; Steven A Lubitz; Christian T Ruff; Marc S Sabatine Journal: JAMA Cardiol Date: 2022-03-01 Impact factor: 14.676
Authors: Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai Journal: J Clin Lipidol Date: 2019-11-29 Impact factor: 4.766